Investor News: Investigation of Myriad Genetics, Inc. (NASDAQ: MYGN) announced

An investigation on behalf of investors of Myriad Genetics, Inc. (NASDAQ: MYGN) shares over potential securities laws violations by Myriad Genetics, Inc. was announced.

Investors who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Myriad Genetics, Inc. (NASDAQ: MYGN) concerning whether a series of statements by Myriad Genetics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 12, 2018, Myriad Genetics, Inc. disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The subpoena requested that the Company produce documents relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.

Those who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com